Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome.

AIMS Methadone is standard pharmacotherapy for opioid-dependent pregnant women, yet the relationship between maternal methadone dose and neonatal abstinence syndrome (NAS) severity is still unclear. This research evaluated whether quantification of fetal methadone and drug exposure via meconium would reflect maternal dose and predict neonatal outcomes. DESIGN Prospective clinical study. SETTING An urban drug treatment facility treating pregnant and post-partum women and their children. PARTICIPANTS Forty-nine opioid-dependent pregnant women received 30-110 mg methadone daily. MEASUREMENTS Maternal methadone dose, infant birth parameters and NAS assessments were extracted from medical records. Thrice-weekly urine specimens were screened for opioids and cocaine. Newborn meconium specimens were quantified for methadone, opioid, cocaine and tobacco biomarkers. FINDINGS There was no relationship between meconium methadone concentrations, presence of opioids, cocaine and/or tobacco in meconium, maternal methadone dose or NAS severity. Opioid and cocaine were also found in 36.7 and 38.8 of meconium specimens, respectively, and were associated with positive urine specimens in the third trimester. The presence of opioids other than methadone in meconium correlated with increased rates of preterm birth, longer infant hospital stays and decreased maternal time in drug treatment. CONCLUSIONS Methadone and its metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) concentrations in meconium did not predict infant birth parameters or NAS severity. Prospective urine testing defined meconium drug detection windows for opiates and cocaine as 3 months, rather than the currently accepted 6 months. The presence of opioids in meconium could be used as a biomarker for infants at elevated risk in the newborn period.

[1]  L. Jansson,et al.  The opioid-exposed newborn: assessment and pharmacologic management. , 2018, Journal of opioid management.

[2]  H. Mactier,et al.  Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources , 2009, BJOG : an international journal of obstetrics and gynaecology.

[3]  E. Ravndal,et al.  Opioid Maintenance Treatment during Pregnancy: Occurrence and Severity of Neonatal Abstinence Syndrome , 2009, European Addiction Research.

[4]  M. Huestis,et al.  A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium , 2009, Analytical and bioanalytical chemistry.

[5]  H. Jones,et al.  Correlations of Maternal Buprenorphine Dose, Buprenorphine, and Metabolite Concentrations in Meconium With Neonatal Outcomes , 2008, Clinical pharmacology and therapeutics.

[6]  E. Pequignot,et al.  Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. , 2007, American journal of obstetrics and gynecology.

[7]  R. de la Torre,et al.  Biological Matrices for the Evaluation of In Utero Exposure to Drugs of Abuse , 2007, Therapeutic drug monitoring.

[8]  Karalee Poschman,et al.  Cost of Hospitalization for Preterm and Low Birth Weight Infants in the United States , 2007, Pediatrics.

[9]  G. Jorch,et al.  Assessment of prenatal tobacco smoke exposure by determining nicotine and its metabolites in meconium , 2007, Human & experimental toxicology.

[10]  M. Huestis,et al.  Concentrations of Methadone in Breast Milk and Plasma in the Immediate Perinatal Period , 2007, Journal of human lactation : official journal of International Lactation Consultant Association.

[11]  M. Huestis,et al.  Bioanalytical procedures for monitoring in utero drug exposure , 2007, Analytical and bioanalytical chemistry.

[12]  H. Jones,et al.  The Impact of Managed Care on Drug-Dependent Pregnant and Postpartum Women and Their Children , 2007, Substance use & misuse.

[13]  G. Anderson.  Using pharmacokinetics to predict the effects of pregnancy and maternal–infant transfer of drugs during lactation , 2006, Expert opinion on drug metabolism & toxicology.

[14]  L. Simmat-Durand,et al.  Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. , 2006, Drug and alcohol dependence.

[15]  H. Aschauer,et al.  Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. , 2006, Addiction.

[16]  A. Rostami-Hodjegan,et al.  Changes to methadone clearance during pregnancy , 2005, European Journal of Clinical Pharmacology.

[17]  M. Leamon,et al.  High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. , 2005, American journal of obstetrics and gynecology.

[18]  B. Lester,et al.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. , 2005, Drug and alcohol dependence.

[19]  H. Jones,et al.  Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  H. Jones,et al.  Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. , 2004, Drug and alcohol dependence.

[21]  R. Couch,et al.  Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? , 2004, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[22]  J. Chennat,et al.  Maternal methadone dose and neonatal withdrawal. , 2003, American journal of obstetrics and gynecology.

[23]  J. Dashe,et al.  Relationship Between Maternal Methadone Dosage and Neonatal Withdrawal , 2002, Obstetrics and gynecology.

[24]  S. Schnoll,et al.  Alterations in methadone metabolism during late pregnancy. , 1999, Journal of addictive diseases.

[25]  D. English,et al.  Assessing the relationship between maternal opiate use and neonatal mortality. , 1998, Addiction.

[26]  H. Van As,et al.  Analysis of methadone and its primary metabolite in meconium. , 1997, Journal of analytical toxicology.

[27]  D. Svikis,et al.  Pregnancy and addiction. A comprehensive care model. , 1996, Journal of substance abuse treatment.

[28]  L. Horwood,et al.  Maternal Methadone Dosage and Neonatal Withdrawal* , 1995, The Australian & New Zealand journal of obstetrics & gynaecology.

[29]  L. Finnegan,et al.  Scientific foundation of clinical practice: opiate use in pregnant women. , 1991, Bulletin of the New York Academy of Medicine.

[30]  N. Buchanan,et al.  Methadone levels and neonatal withdrawal , 1991, Journal of paediatrics and child health.

[31]  E. Ostrea,et al.  Drug screening of meconium in infants of drug-dependent mothers: an alternative to urine testing. , 1989, The Journal of pediatrics.

[32]  L. Finnegan,et al.  Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. , 1986, Neurobehavioral toxicology and teratology.

[33]  R. Harper,et al.  Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. , 1977, American journal of obstetrics and gynecology.

[34]  C. Pippenger,et al.  Pharmacologic observations on the neonatal withdrawal syndrome. , 1976, The Journal of pediatrics.

[35]  C. Inturrisi,et al.  Methadone assays in pregnant women and progeny. , 1975, American journal of obstetrics and gynecology.

[36]  M. Strauss,et al.  Methadone maintenance during pregnancy: pregnancy, birth, and neonate characteristics. , 1974, American journal of obstetrics and gynecology.

[37]  L. Cordero,et al.  High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. , 2009, American journal of obstetrics and gynecology.

[38]  G. Hankins,et al.  Transfer of methadone across the dually perfused preterm human placental lobule. , 2008, American journal of obstetrics and gynecology.

[39]  J. Greenspan,et al.  Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome , 2007, Journal of perinatal medicine.

[40]  H. Jones,et al.  Mood disorders affect drug treatment success of drug-dependent pregnant women. , 2007, Journal of substance abuse treatment.

[41]  G. Hankins,et al.  Bidirectional transfer of methadone across human placenta. , 2005, Biochemical pharmacology.

[42]  M. Behnke,et al.  Detection of cocaine exposure in the neonate. Analyses of urine, meconium, and amniotic fluid from mothers and infants exposed to cocaine. , 1994, Archives of pathology & laboratory medicine.

[43]  T. M. Doberczak,et al.  Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. , 1993, Obstetrics and gynecology.

[44]  L. Finnegan,et al.  Prenatal narcotic exposure: perinatal and developmental effects. , 1989, Neurotoxicology.

[45]  P. DePetrillo,et al.  Altered methadone pharmacokinetics in pregnancy: implications for dosing. , 1989, Journal of substance abuse.

[46]  M. Chiarotti,et al.  Methadone in pregnancy: clinical-toxicological aspects. , 1986, Journal of toxicology. Clinical toxicology.

[47]  M. Kreek.  Methadone disposition during the perinatal period in humans. , 1979, Pharmacology, biochemistry, and behavior.

[48]  L. Finnegan,et al.  Current concepts in the management of the pregnant opiate addict. , 1975, Addictive diseases.

[49]  A. Schecter,et al.  Analyses of methadone and other drugs in maternal and neonatal body fluids: use in evaluation of symptoms in a neonate of mother maintained on methadone. , 1974, The American journal of drug and alcohol abuse.